| Net Earnings (Loss) Per Share |
Note
11 - Net Earnings (Loss) Per Share
Basic
earnings (loss) per share excludes dilution and is computed by dividing income available to common stockholders by the weighted-average
number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur
if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance
of common stock that shared in the earnings of the entity. Diluted earnings (loss) per share also utilizes the treasury stock method
which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the
if-converted method for convertible debt.
The
following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss
per share (in thousands):
Schedule
of Reconciliation of the Weighted Average Number of Common Shares Outstanding used in Calculating Basic and Diluted Net Loss
Per Share
| |
|
June
30, 2026 |
|
|
June
30, 2025 |
|
|
June
30, 2026 |
|
|
June
30, 2025 |
|
| |
|
For
the three months ended |
|
|
For
the six months ended |
|
| |
|
June
30, 2026 |
|
|
June
30, 2025 |
|
|
June
30, 2026 |
|
|
June
30, 2025 |
|
| Loss from continuing
operations after income taxes |
|
$ |
(3,051 |
) |
|
$ |
(4,472 |
) |
|
$ |
(8,226 |
) |
|
$ |
(9,150 |
) |
| Income
from discontinued operations, net of tax |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
8,644 |
|
| Net
loss |
|
$ |
(3,051 |
) |
|
$ |
(4,472 |
) |
|
$ |
(8,226 |
) |
|
$ |
(506 |
) |
| Weighted average common shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Basic |
|
|
14,016 |
|
|
|
4,154 |
|
|
|
13,171 |
|
|
|
3,840 |
|
| Diluted |
|
|
14,016 |
|
|
|
4,154 |
|
|
|
13,171 |
|
|
|
3,840 |
|
| Net earnings (loss) per share: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Loss
from continuing operations, basic and diluted |
|
$ |
(0.22 |
) |
|
$ |
(1.08 |
) |
|
$ |
(0.62 |
) |
|
$ |
(2.38 |
) |
| Income
from discontinued operations, basic and diluted |
|
$ |
- |
|
|
$ |
- |
|
|
$ |
- |
|
|
$ |
2.25 |
|
| Net
loss (earnings) per share, basic and diluted |
|
$ |
(0.22 |
) |
|
$ |
(1.08 |
) |
|
$ |
(0.62 |
) |
|
$ |
(0.13 |
) |
ProPhase
Labs, Inc. and Subsidiaries
Notes
to Condensed Consolidated Financial Statements
(unaudited)
The
following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive
effect (in thousands):
Schedule of Anti-dilutive Securities Excluded from the Income Per Share Computation
| Anti-dilutive securities |
|
June 30, 2026 |
|
|
June 30, 2025 |
|
|
June 30, 2026 |
|
|
June 30, 2025 |
|
| |
|
For the three months ended |
|
|
For the six months ended |
|
| Anti-dilutive securities |
|
June 30, 2026 |
|
|
June 30, 2025 |
|
|
June 30, 2026 |
|
|
June 30, 2025 |
|
| Common stock purchase warrants |
|
|
997 |
|
|
|
174 |
|
|
|
997 |
|
|
|
174 |
|
| Stock options |
|
|
478 |
|
|
|
445 |
|
|
|
478 |
|
|
|
445 |
|
| Convertible notes |
|
|
13,773 |
|
|
|
- |
|
|
|
13,773 |
|
|
|
- |
|
| Anti-dilutive securities |
|
|
15,248 |
|
|
|
619 |
|
|
|
15,248 |
|
|
|
619 |
|
|